{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:47:26Z","timestamp":1770886046667,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lundbeck LLC, Deerfield, IL, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Eptinezumab 100\u00a0mg and 300\u00a0mg met the primary efficacy endpoint in both PROMISE clinical trials, significantly reducing frequency of monthly migraine days over Weeks 1\u201212. The objective of this analysis was to assess the clinical response to eptinezumab 100\u00a0mg and 300\u00a0mg within the pivotal phase 3 PROMISE-1 and PROMISE-2 studies to potentially identify subsets of patients with meaningful differences between doses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients from PROMISE-1 (NCT02559895) and PROMISE-2 (NCT02974153) trials were divided into subgroups based on demographic and migraine characteristics, and baseline questionnaire responses. For each subgroup, the overall likelihood of achieving\u2009\u2265\u200950% migraine responder rate (MRR) over Weeks 1\u201312 and Weeks 13\u201324 with either eptinezumab 100\u00a0mg or 300\u00a0mg was calculated using odds ratios (with associated confidence intervals) and compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In PROMISE-1 (episodic migraine) and PROMISE-2 (chronic migraine), the likelihood of achieving\u2009\u2265\u200950% MRR over Weeks 1\u201312 and Weeks 13\u201324 was roughly equivalent for patients receiving either dose level of eptinezumab. Given the number of comparisons performed, sporadic apparent differences were seen but no replicated patterns between studies emerged. In PROMISE-1, no differences were observed in any subgroup over Weeks 1\u201312. In PROMISE-2, patients reporting\u2009&lt;\u200915 monthly migraine days at baseline, <jats:italic>any problems<\/jats:italic> with mobility per the EQ-5D-5L, or a social functioning score\u2009&gt;\u200945.0 per the 36-item Short-Form Health Survey (SF-36), appeared more likely to achieve\u2009\u2265\u200950% MRR with 300\u00a0mg over Weeks 1\u201312, with none of these being apparent in PROMISE-1.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Overall, these data suggest that across PROMISE-1 and PROMISE-2, there were no meaningful differences in the likelihood of achieving\u2009\u2265\u200950% MRR between the eptinezumab dose levels in the majority of patient subgroups. In the few subgroups that displayed small, but potentially meaningful differences, patients were more likely to achieve\u2009\u2265\u200950% MRR with eptinezumab 300\u00a0mg; however, minimal consistency across both studies and time periods was noted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial Registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov.<\/jats:p>\n                <jats:p>PROMISE-1: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02559895\">NCT02559895<\/jats:ext-link>.<\/jats:p>\n                <jats:p>PROMISE-2: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02974153\">NCT02974153<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01418-8","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T10:12:54Z","timestamp":1650276774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2"],"prefix":"10.1186","volume":"23","author":[{"given":"Rami","family":"Apelian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Hirman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Asher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"key":"1418_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"VL Feigin","year":"2019","unstructured":"Feigin VL, Nichols E, Alam T et al (2019) Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:459\u2013480. https:\/\/doi.org\/10.1016\/S1474-4422(18)30499-X","journal-title":"Lancet Neurol"},{"key":"1418_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jamaneurol.2020.4152","volume":"78","author":"VL Feigin","year":"2021","unstructured":"Feigin VL, Vos T, Alahdab F et al (2021) Burden of Neurological Disorders Across the US From 1990\u20132017. JAMA Neurol 78:165. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4152","journal-title":"JAMA Neurol"},{"key":"1418_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/S13311-018-0622-7","volume":"15","author":"B Raffaelli","year":"2018","unstructured":"Raffaelli B, Reuter U (2018) The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy. NeuroRx 15:324\u2013335. https:\/\/doi.org\/10.1007\/S13311-018-0622-7","journal-title":"NeuroRx"},{"key":"1418_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1124\/JPET.119.264671\/-\/DC1","volume":"374","author":"LF Garcia-Martinez","year":"2020","unstructured":"Garcia-Martinez LF, Raport CJ, Ojala EW et al (2020) Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide. J Pharmacol Exp Ther 374:93\u2013103. https:\/\/doi.org\/10.1124\/JPET.119.264671\/-\/DC1","journal-title":"J Pharmacol Exp Ther"},{"key":"1418_CR5","doi-asserted-by":"publisher","unstructured":"Baker B, Schaeffler B, Beliveau M, et al (2020) Population pharmacokinetic and exposure\u2010response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Persp. 8:e00567. https:\/\/doi.org\/10.1002\/prp2.567","DOI":"10.1002\/prp2.567"},{"key":"1418_CR6","unstructured":"(2021) VYEPTI [package insert]. Bothell, WA"},{"key":"1418_CR7","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology 94:e1365\u2013e1377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169","journal-title":"Neurology"},{"key":"1418_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R et al (2020) Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40:241\u2013254. https:\/\/doi.org\/10.1177\/0333102420905132","journal-title":"Cephalalgia"},{"key":"1418_CR9","doi-asserted-by":"publisher","unstructured":"Ailani J, Burch RC, Robbins MS (2021) The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 61:1021\u20131039. https:\/\/doi.org\/10.1111\/head.14153","DOI":"10.1111\/head.14153"},{"key":"1418_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW et al (2018) Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38:815\u2013832. https:\/\/doi.org\/10.1177\/0333102418758283","journal-title":"Cephalalgia"},{"key":"1418_CR11","unstructured":"About Adult BMI | Healthy Weight, Nutrition, and Physical Activity | CDC. Accessed 9 Mar 2022. https:\/\/www.cdc.gov\/healthyweight\/assessing\/bmi\/adult_bmi\/index.html."},{"key":"1418_CR12","unstructured":"Age and Sex Composition in the United States: 2019. Accessed 9 Mar 2022. https:\/\/www.census.gov\/data\/tables\/2019\/demo\/age-and-sex\/2019-age-sex-composition.html."},{"key":"1418_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/S10194-021-01222-W","volume":"22","author":"J Jedynak","year":"2021","unstructured":"Jedynak J, Eross E, Gendolla A et al (2021) Shift from high-frequency to low-frequency episodic migraine in patients treated with galcanezumab: results from two global randomized clinical trials. J Headache Pain 22:48. https:\/\/doi.org\/10.1186\/S10194-021-01222-W","journal-title":"J Headache Pain"},{"key":"1418_CR14","doi-asserted-by":"publisher","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA, et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19:814\u2013825. https:\/\/doi.org\/10.1016\/S1474-4422(20)30279-9","DOI":"10.1016\/S1474-4422(20)30279-9"},{"key":"1418_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S10194-019-1024-X","volume":"20","author":"SD Silberstein","year":"2019","unstructured":"Silberstein SD, Stauffer VL, Day KA et al (2019) Galcanezumab in episodic migraine: Subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain 20:1\u201311. https:\/\/doi.org\/10.1186\/S10194-019-1024-X","journal-title":"J Headache Pain"},{"key":"1418_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S10072-021-05837-4","volume":"2021","author":"M Simone","year":"2022","unstructured":"Simone M, Giulia DA, Claudia A et al (2022) Task-switching abilities in episodic and chronic migraine. Neurol Sci 2021:1\u20138. https:\/\/doi.org\/10.1007\/S10072-021-05837-4","journal-title":"Neurol Sci"},{"key":"1418_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/CJN.2021.75","volume":"00","author":"F Amoozegar","year":"2021","unstructured":"Amoozegar F, Khan Z, Oviedo-Ovando M et al (2021) The Burden of Illness of Migraine in Canada: New Insights on Humanistic and Economic Cost. Can J Neurol Sci 00:1\u201314. https:\/\/doi.org\/10.1017\/CJN.2021.75","journal-title":"Can J Neurol Sci"},{"key":"1418_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/S40120-020-00196-2\/TABLES\/3","volume":"9","author":"MJ Doane","year":"2020","unstructured":"Doane MJ, Gupta S, Fang J et al (2020) The Humanistic and Economic Burden of Migraine in Europe: a Cross-Sectional Survey in Five Countries. Neurol Ther 9:535\u2013549. https:\/\/doi.org\/10.1007\/S40120-020-00196-2\/TABLES\/3","journal-title":"Neurol Ther"},{"key":"1418_CR19","doi-asserted-by":"publisher","unstructured":"Lipton RB, Nicholson RA, Reed ML, et al (2022) Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study. Headache: J Head Face Pain 62:122\u2013140. https:\/\/doi.org\/10.1111\/head.14259","DOI":"10.1111\/head.14259"},{"key":"1418_CR20","doi-asserted-by":"publisher","unstructured":"Buse DC, Reed ML, Fanning KM, et al (2020) Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache: J Head Face Pain 60:2340\u20132356. https:\/\/doi.org\/10.1111\/HEAD.13966","DOI":"10.1111\/HEAD.13966"},{"key":"1418_CR21","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/head.14120","volume":"61","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Dodick DW, Ailani J et al (2021) Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome. Headache 61:766\u2013776. https:\/\/doi.org\/10.1111\/head.14120","journal-title":"Headache"},{"key":"1418_CR22","doi-asserted-by":"publisher","unstructured":"Lipton RB, Goadsby PJ, Dodick DW, et al Evaluating the Clinical Utility of the Patient-Identified Most Bothersome Symptom Measure from PROMISE-2 for Research in Migraine Prevention. Headache. In Press. https:\/\/doi.org\/10.1111\/head.14295","DOI":"10.1111\/head.14295"},{"key":"1418_CR23","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/S11136-011-9903-X","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727\u20131736. https:\/\/doi.org\/10.1007\/S11136-011-9903-X","journal-title":"Qual Life Res"},{"key":"1418_CR24","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/S11136-020-02650-Y\/FIGURES\/1","volume":"30","author":"R Jiang","year":"2021","unstructured":"Jiang R, Janssen MFB, Pickard AS (2021) US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res 30:803\u2013816. https:\/\/doi.org\/10.1007\/S11136-020-02650-Y\/FIGURES\/1","journal-title":"Qual Life Res"},{"key":"1418_CR25","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","volume":"25","author":"J Ware Jr","year":"2000","unstructured":"Ware J Jr (2000) SF-36 health survey update. Spine 25:3130\u20133139. https:\/\/doi.org\/10.1097\/00007632-200012150-00008","journal-title":"Spine"},{"key":"1418_CR26","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB et al (2003) A six-item short-form survey for measuring headache impact: The HIT-6. Qual Life Res 12:963\u2013974. https:\/\/doi.org\/10.1023\/A:1026119331193","journal-title":"Qual Life Res"},{"key":"1418_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-021-01220-y","volume":"22","author":"Z Yan","year":"2021","unstructured":"Yan Z, Xue T, Chen S et al (2021) Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials. J Headache Pain 22:10. https:\/\/doi.org\/10.1186\/s10194-021-01220-y","journal-title":"J Headache Pain"},{"key":"1418_CR28","doi-asserted-by":"publisher","unstructured":"TR Smith, ELH Spierings, R Cady, et al (2021) Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain 22. https:\/\/doi.org\/10.1186\/S10194-021-01227-5","DOI":"10.1186\/S10194-021-01227-5"},{"key":"1418_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano D, Lipton RB, Scher AI et al (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 18:101. https:\/\/doi.org\/10.1186\/s10194-017-0787-1","journal-title":"J Headache Pain"},{"key":"1418_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-022-01387-y","volume":"23","author":"DC Buse","year":"2022","unstructured":"Buse DC, Winner PK, Charleston L, et al (2022) Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine. J Headache Pain 23:1\u201312. https:\/\/doi.org\/10.1186\/S10194-022-01387-Y","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01418-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01418-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01418-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T11:03:15Z","timestamp":1650366195000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01418-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1418"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01418-8","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,18]]},"assertion":[{"value":"2 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for each study was provided by the independent ethics committee or institutional review board of the study sites. The studies were each conducted in accordance with Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, and all applicable regulatory requirements. Patients provided written informed consent prior to initiation of any study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R. Apelian is a member of the speaker bureau for Lundbeck; advisor\/consultant\/speaker for Allergan\/Abbvie, Biohaven, and Eli Lilly.L. Boyle and D. Asher are full-time employees of Lundbeck.J. Hirman is an employee of Pacific Northwest Statistical Consulting, Inc., a contracted service provider of biostatistical resources for Lundbeck.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}